Chimerix (CMRX) Competitors $8.54 0.00 (0.00%) As of 04/21/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CMRX vs. VKTX, MTSR, AKRO, ALVO, CPRX, CRNX, SRRK, MRUS, MOR, and PTGXShould you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Viking Therapeutics (VKTX), Metsera (MTSR), Akero Therapeutics (AKRO), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), Merus (MRUS), MorphoSys (MOR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Chimerix vs. Viking Therapeutics Metsera Akero Therapeutics Alvotech Catalyst Pharmaceuticals Crinetics Pharmaceuticals Scholar Rock Merus MorphoSys Protagonist Therapeutics Chimerix (NASDAQ:CMRX) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Do institutionals & insiders believe in CMRX or VKTX? 45.4% of Chimerix shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 13.1% of Chimerix shares are owned by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, CMRX or VKTX? Chimerix has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Is CMRX or VKTX more profitable? Viking Therapeutics' return on equity of -11.93% beat Chimerix's return on equity.Company Net Margins Return on Equity Return on Assets ChimerixN/A -50.78% -44.94% Viking Therapeutics N/A -11.93%-11.57% Which has stronger valuation and earnings, CMRX or VKTX? Chimerix has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChimerix$212K3,778.71-$82.10M-$0.99-8.63Viking TherapeuticsN/AN/A-$109.96M-$1.15-24.93 Do analysts recommend CMRX or VKTX? Chimerix presently has a consensus price target of $8.53, suggesting a potential downside of 0.08%. Viking Therapeutics has a consensus price target of $87.15, suggesting a potential upside of 203.99%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer CMRX or VKTX? Viking Therapeutics received 239 more outperform votes than Chimerix when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 62.66% of users gave Chimerix an outperform vote. CompanyUnderperformOutperformChimerixOutperform Votes39662.66% Underperform Votes23637.34% Viking TherapeuticsOutperform Votes63580.08% Underperform Votes15819.92% Does the media refer more to CMRX or VKTX? In the previous week, Viking Therapeutics had 15 more articles in the media than Chimerix. MarketBeat recorded 15 mentions for Viking Therapeutics and 0 mentions for Chimerix. Viking Therapeutics' average media sentiment score of 1.37 beat Chimerix's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Chimerix Neutral Viking Therapeutics Positive SummaryViking Therapeutics beats Chimerix on 12 of the 17 factors compared between the two stocks. Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRX vs. The Competition Export to ExcelMetricChimerixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$801.09M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-9.099.1426.8320.05Price / Sales3,778.71255.59394.87116.44Price / CashN/A65.8538.2534.62Price / Book3.946.546.874.61Net Income-$82.10M$143.51M$3.22B$248.19M7 Day PerformanceN/A5.60%6.82%2.97%1 Month Performance-0.06%10.06%13.72%16.58%1 Year Performance775.90%-0.86%18.31%8.16% Chimerix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRXChimerix0.5605 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastVKTXViking Therapeutics4.4673 of 5 stars$27.50-3.3%$87.15+216.9%-57.5%$3.09BN/A-27.5020Positive NewsMTSRMetseraN/A$28.96-1.9%$47.00+62.3%N/A$3.04BN/A0.0081AKROAkero Therapeutics3.7479 of 5 stars$38.14-1.9%$82.33+115.9%+136.2%$3.04BN/A-10.1730Insider TradeALVOAlvotech1.806 of 5 stars$10.07-3.7%$18.00+78.7%-27.6%$3.04B$585.60M-5.444CPRXCatalyst Pharmaceuticals4.6613 of 5 stars$24.63+1.1%$32.29+31.1%+45.9%$3.00B$534.65M20.8780Positive NewsCRNXCrinetics Pharmaceuticals3.7086 of 5 stars$30.95-0.9%$73.00+135.9%-38.0%$2.90B$760,000.00-8.30210SRRKScholar Rock4.0579 of 5 stars$30.16-1.3%$42.67+41.5%+151.9%$2.86B$33.19M-12.83140Earnings ReportAnalyst RevisionMRUSMerus3.2572 of 5 stars$41.36-0.5%$84.54+104.4%+0.9%$2.86B$54.73M-10.4737Earnings ReportAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.2827 of 5 stars$45.57+2.4%$65.44+43.6%+49.1%$2.82B$207.80M17.13120News CoverageAnalyst Forecast Related Companies and Tools Related Companies Viking Therapeutics Competitors Metsera Competitors Akero Therapeutics Competitors Alvotech Competitors Catalyst Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Scholar Rock Competitors Merus Competitors MorphoSys Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMRX Stock Free CMRX Stock Alerts